©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
The Rac Target NADPH Oxidase p67 Interacts Preferentially with Rac2 Rather Than Rac1 (*)

(Received for publication, September 6, 1995; and in revised form, October 6, 1995 )

Olivier Dorseuil (1)(§) Louise Reibel (1) Gary M. Bokoch (2) Jacques Camonis (3) Gerard Gacon (1)(¶)

From the  (1)Institut Cochin de Génétique Moléculaire, INSERM Unité 257, 24 rue du Fbg St. Jacques, 75014 Paris, France, the (2)Departments of Immunology and Cell Biology, The Scripps Research Institute, La Jolla, California 92037, and (3)INSERM Unité 248, 10 Avenue de Verdun, 75010 Paris, France

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

NADPH oxidase is a plasma membrane enzyme of phagocytes generating superoxide anions which serve as bactericidal agents. Activation of this multimolecular enzyme minimally requires assembly at the membrane with flavocytochrome b of cytosolic components p47, p67, and Rac proteins. Rac1 and Rac2 are 92% homologous cytosolic small GTPase proteins. Both Rac1 and Rac2 have been implicated with NADPH oxidase activation in vitro; however, Rac2 is largely predominant in human phagocytes. Here, using the yeast two-hybrid system, we provide data demonstrating in vivo interactions between human p47, p67, and Rac proteins. Rac proteins interact with p67 in a GTP-dependent manner, but do not interact with p47. Moreover, Rac effector site mutants, which are known to be inactive in NADPH oxidase, lose their interaction with p67; Rac2L61 mutant, which has an increased NADPH oxidase affinity, shows an increased affinity for p67. Finally, we observe that p67 interacts 6-fold better with Rac2 than with Rac1. We also show a strong intracellular interaction between p47 and p67. These results indicate that activated Rac can regulate NADPH oxidase by interacting with p67 and that Rac2 is the main p67-interacting GTPase in human cells.


INTRODUCTION

NADPH oxidase is a multicomponent plasma membrane-bound enzyme used by phagocytes to produce superoxide anions in response to stimuli from microbial infections(1, 2, 3) . This massive production of oxygen metabolites, known as the respiratory burst, is an efficient bactericidal mechanism as underscored by severe infections in case of enzyme deficiency in chronic granulomatous disease(4) .

Early biochemical and genetic studies (5, 6) in combination with reconstitution of enzyme activity in a cell-free system, characterized the minimal structure of the enzyme(7, 8) . This includes the transmembrane flavocytochrome b, consisting of subunits gp91 and p22, and three regulatory cytosolic proteins, p47, p67(9, 10) , and the more recently isolated small GTPase Rac1 or Rac2(11, 12) . Rac1 and Rac2 are 92% homologous Ras-like proteins, initially isolated from cell cytosol, Rac1 from guinea pig macrophages, and Rac2 from human neutrophils, as the GTP-binding protein enhancing superoxide generation in the cell-free assay(11, 12) . The physiological requirement for Rac proteins in NADPH oxidase has then been demonstrated in a whole cell assay, using rac antisense oligonucleotides or a dominant-negative mutant(13, 14) .

In addition, the small GTPase Rap1a, found tightly associated with membranous cytochrome b(15) , although dispensable in the cell-free system, is required for enzyme activity in a whole cell environment(14, 16) . The recently isolated cytosolic protein p40(17, 18) has been reported to interact with p47 and p67 components, and may play the role of a chaperone in the activated complex(19) .

How is Rac regulating the NADPH oxidase? Clearly the nucleotide state of Rac proteins controls the activity of NADPH oxidase: there is an absolute requirement for GTP in the cell-free system, GTP-preloaded Rac activates the enzyme, and factors which modulate the GTP/GDP state of Rac also modulate the activation of the enzyme(1) . It has been shown that Bcr, a complex protein whose GTPase activating function acts on Rac in vitro, regulates the activation of the enzyme in vivo(20) . An intact Rac effector domain is also required for enzyme activation, as shown by the inefficiency of Rac effector mutants in cell-free assays(21, 22, 23) . It has been reported that Rac2L61, a GTPase-deficient mutant (therefore mainly in the GTP-bound form) has at least a 3-fold enhanced affinity for the enzyme, as compared to wild type or RacV12 proteins(22) . Both Rac1 and Rac2 proteins are able to activate the enzyme and are roughly equivalent for activation of the recombinant cell-free system(24, 25) . However, in the presence of human neutrophil cytosol in the assay, Rac2 was a more potent activator than Rac1(24) .

Upon cell stimulation, cytosolic regulatory proteins translocate to the plasma membrane and/or membrane-associated cytoskeleton to form the active enzyme complex(26, 27, 28) . Components, p47 and p67, tightly associated as a cytosolic complex(18, 29) , translocate to the membrane where p47 interacts with cytochrome b-subunit p22, probably through SH3 and proline-rich domain interactions(30, 31) . Although contradictory data have been published about Rac recruitment at the membrane(32) , overall it appears that Rac-GTP activates NADPH oxidase at the membrane level (33) and that in whole cells, Rac translocation seems to correlate with enzyme activation(27, 28, 34, 35) .

Interactions between p47 and p67 have been widely documented recently(30, 31, 36, 37, 38, 39) , but direct interactions of Rac proteins with NADPH oxidase components are so far poorly described. After we began this study, Diekmann et al.(21) reported, using glutathione S-transferase fusion proteins, that Rac1-GTP was able to interact with p67 through its effector domain, suggesting that p67 was a molecular target for Rac proteins. However, several points can be raised about this result: a 100 times molar excess of p67 over Rac recombinant proteins was necessary to observe a rather weak interaction; only Rac1 has been studied even though Rac2, mainly expressed in NADPH oxidase expressing cells, is highly predominant over Rac1 in human phagocytes(34, 40) ; and in a more biological environment, Sf9 cells overexpressing p47, p67, and p21Rac1, Rac1-p67complex was undetectable(33) . Another study (41) also very recently reported a weak interaction in vitro between Rac1-GTP and p67 recombinants proteins.

Here, we have used a two-hybrid system in yeast (42, 43, 44) to study in an intracellular environment, interactions between the three regulatory cytosolic factors, p47, p67, and p21Rac. Our results provide clear evidence showing that p47 and p67 interact in a stable complex, that p67 is an in vivo target for Rac-GTP, and that Rac2 in a whole cell system, interacts much better than Rac1 with p67.


EXPERIMENTAL PROCEDURES

Two-hybrid System: Yeast, Vectors, and Methods

In order to investigate protein-protein interactions in the two-hybrid system, we used the yeast strain HF7c (45) containing two GAL4-inducible reporter genes, HIS3 and LacZ, or the yeast strain L40 (kindly provided by Dr. A. Vojtek) where the same reporter genes are under the control of multicopies of LexA operon(46) .

Proteins fused to the GAL4 DNA binding domain were expressed from plasmid pGBT10(45) . Proteins fused to the GAL4 activation domain (GAL4 AD) (^1)were expressed from plasmid pGAD-GH(47) . Proteins fused to the LexA protein were expressed from either plasmid pBTM116 (46) or from pVJL10, a derivative of pBTM116 with modified polylinker. (^2)HF7c or L40 cells were cotransformed with pairs of two-hybrid plasmids and selected by growth on medium lacking tryptophane and leucine. Cotransformed colonies were patched on the same selective medium and subsequently replicated to test for protein interaction, using beta-galactosidase activity assay on filter with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside or using growth in the absence of histidine in the medium, see indications in figure legends(44, 48) .

Cloning of rac, p47, and p67 in Two-hybrid Plasmids

Alleles of rac1, rac1-wt, rac1-V12, rac1-V12N17, rac1-V12A35 and rac1-V12A38 have a Ser-189 mutation and are fused to a Myc epitope(49) . They were amplified by polymerase chain reaction when necessary and cloned in-frame with LexA protein. p47 and p67 cDNAs, a gift of Dr. T. Leto, were cloned in-frame with GAL4 DNA binding domain in plasmid pGBT10 and, in-frame with GAL4 AD in plasmid pGAD-GH. Complementary DNA of rac2-V12, rac2-N17, and rac2-L61, amplified by polymerase chain reaction when necessary, were inserted in-frame with LexA protein. In order to insure correct comparisons between rac1 and rac2 alleles, rac1 alleles used for such comparisons (Fig. 4) were reamplified by polymerase chain reaction and cloned, without myc-tag and Ser-189 mutation, in-frame with LexA protein. All alleles derived from polymerase chain reaction products were entirely sequenced.


Figure 4: Comparison between Rac1 and Rac2 proteins for interaction with p67. In yeast strain L40, Rac1V12 and Rac2V12 fused to LexA, were tested for interaction with p67fused to the GAL4 activation domain. Protein interactions are demonstrated by histidine-independent growth or beta-galactosidase activity. A, growth in the absence of histidine is shown in the right column (-His), observations at 72 h. Control growth of cotransformed yeast in presence of histidine is shown on left column (+His). B, beta-galactosidase activity on a filter assay, observations at 24 h. C, beta-galactosidase activity quantified by a liquid assay.



Analysis of LexA Fusion Proteins Expression

Total yeast extracts were prepared in SDS sample buffer according to standard procedures(48) , resolved by SDS-polyacrylamide gel electrophoresis (10% gel), and electroblotted onto nitrocellulose. Blots were processed as described (13) with rabbit anti-LexA antibodies kindly provided by Dr. P. Moreau(50) , and developed using the ECL detection system (Amersham).

Quantitative Assay for beta-Galactosidase Activity

In addition to the non-quantitative beta-galactosidase test on filter, we used this protocol when enzyme activity needed to be quantified. Cotransformed yeast colonies, grown in selective liquid medium lacking leucine and tryptophan, were harvested while in the exponential growth phase. Similar numbers of cells were processed for the different cotransformed yeasts. Cells were disrupted by vortexing with glass beads, at 4 °C in 0.1 M Tris, pH 8. Protein extracts were quantified and used to determine beta-galactosidase activity in: 100 mM phosphate buffer, pH 7, 10 mM KCl, 1 mM MgSO(4), and 50 mM beta-mercaptoethanol, with O-nitrophenyl-beta-D-galactopyranoside as substrate (0.7 mg/ml final). Reactions were carried out at 30 °C, stopped by addition of 250 mM sodium carbonate, and enzyme activity determined by measuring absorbance at 420 nm(51) . Linearity of beta-galactosidase activity versus quantity of yeast cell extract was checked.


RESULTS AND DISCUSSION

Since previous evidence suggested an interaction between p67 and p47(18, 29) , we first tested the ability of these two proteins to interact in the two-hybrid system. A plasmid expressing p47 fused to the GAL4 activation domain and a plasmid expressing p67 fused to the GAL4 DNA binding domain were introduced into yeast reporter strain HF7c(45) . Transformants were tested for their ability to grow in the absence of histidine. The interaction between a hybrid of SNF1 and a hybrid of SNF4, two yeast proteins known to interact with each other, provided a positive control(42) . All transformants grew at similar rates in the presence of histidine, but only cells containing GAL4 AD-p47 and GAL4 DNA binding domain-p67 hybrids maintained their growth in the absence of histidine (Fig. 1). The reciprocal combination GAL4 AD-p67/GAL4 DNA binding domain-p47 had the same effect. Growth capacity on medium lacking histidine was not induced when p47 or p67 were replaced by SNF1 or SNF4 proteins (Fig. 1). Therefore, we conclude that expression of the reporter gene HIS3 results from the interaction between p47 and p67. This interaction was initially suspected from observations showing that a large protein complex found in phagocyte cytosol contained a fraction of both proteins(18, 29) , and that p67 translocation to the membrane depended on the presence of p47(52) . A direct interaction between both proteins in cell cytosol, involving SH3 and proline-rich domains of each protein has been observed(30, 33, 36, 37) . Consistent with these data, the results of our two-hybrid study provide evidence for the formation of a complex between p47 and p67 proteins in the intact cell. They further indicate that this complex is independent of Rac. p47-p67 interactions in the two-hybrid system provide a means for investigating in an intracellular environment how this interaction could be modulated by biological signals. It should be feasible, for example, to stimulate or inhibit in yeast, pathways known to activate NADPH oxidase in phagocytes (protein kinase C activation or arachidonate synthesis) and to analyze their effect on the p47-p67 complex.


Figure 1: Interaction between p47 and p67. Interactions between proteins are tested in yeast strain HF7c. Cells were cotransformed with pairs of recombinant plasmids, one expressing the indicated protein fused to the GAL4 DNA binding domain (column I) and the other expressing the indicated protein fused to GAL4 activation domain (column II). Cotransformed cells, growing on selective plates lacking tryptophan and leucine but in the presence of histidine, are shown in the left lane. Interactions between two-hybrid proteins are indicated by histidine-independent growth as shown in the right lane, observations at 36 h. Yeast proteins SNF1 and SNF4 were used as positive control.



Interactions between p21 and p47 or p67 were first investigated using the same two-hybrid system based on GAL4 reconstitution in reporter yeast HF7c. Different alleles of Rac1 were used: Rac1 wild type; Rac1V12, an activated mutant of Rac1 blocked in GTP-bound form; and Rac1V12N17, a dominant-negative mutant of Rac1 blocked in the GDP-bound form(49) . Rac proteins undergo an isoprenylation of their C-terminal part, at cysteine 189, which probably allows this cytosolic protein to bind membrane(53) . To avoid decreasing detection sensitivity due to partial membrane localization of proteins in yeast, as already reported in two-hybrid study of Ras-Raf interactions(54) , we tested Rac1 alleles with a serine 189 mutation, thus preventing C-terminal isoprenylation and membrane localization. In the first set of experiments (data not shown) cotransformed colonies expressing the different Rac alleles with p47 or p67 proteins were checked for their ability to grow in the absence of histidine. Only transformants expressing Rac1V12 in combination with p67 showed a significant histidine-independent growth. Although the signal was rather weak, it was significant and suggested that an activated form of Rac1 was required for Rac1-p67 interaction. To increase signal intensity, we decided to use another yeast two-hybrid system, which in our hands appeared more sensitive.

This system, based on LexA DNA binding protein and yeast strain L40 (46) , which carries HIS3 and LacZ as reporter genes, allowed us to make a more detailed analysis of Rac-p67 interactions. The same Rac1-serine 189 alleles were used as fusion protein with LexA, to look at interactions with p67 or p47 fused to the GAL4 activation domain (Fig. 2). The interaction between RasV12 hybrid and c-Raf1 hybrid provided a positive control in L40 cells (Fig. 2B). The various cotransformed cells were able to grow at similar rates in the presence of histidine, indicating no particular toxicity of expressed hybrid proteins. The ability to grow in the absence of histidine was clearly induced when Rac1V12 and p67 hybrid proteins were coexpressed (Fig. 2A). The ``deactivation'' of Rac1V12 by the Asn-17 mutation resulted in a dramatic decrease of histidine-independent growth of Rac1V12NI7-p67 transformants (Fig. 2A). By contrast, Rac1V12-p47 or Rac1V12NI7-p47 combinations were completely inefficient in promoting histidine-independent growth (Fig. 2A). These results therefore indicate that only the activated GTP-bound form of Rac1 is capable of interacting with cytosolic regulator of NADPH oxidase, p67, but not with p47. We also conclude that isoprenylation of the C-terminal part of Rac proteins is not essential for Rac-p67 interactions, consistent with previous studies of Rac activity in a cell-free system(24) .


Figure 2: Interaction between Rac1V12 and p67. Proteins expressed as fusion with GAL4 activation domain (column II) were tested for interaction with various small GTPases fused to LexA protein (column I), in yeast strain L40. Growth of cotransformed yeast, in the presence of histidine, is shown in the left lane. Interactions between proteins are demonstrated by histidine-independent growth in the right lane (-His), observations at 72 h. A, interactions between Rac1V12 or Rac1V12N17 with p47 or p67. B, interactions between p67 and Rac effector mutants or various small GTPases. Ras and Raf proteins were used as a positive control. C, immunoblot showing expression of the various LexA fusion proteins, from yeast used in A and B. 1, LexA without fusion; 2, LexA-Rac1V12; 3, LexA-RhoBV14; 4, LexA-RhoGV12; 5, LexA-Rac1V12A35; 6, LexA-Rac1V12A38; 7, LexA-RasV12; 8, LexA-Rac1V12; 9, LexA-Rac1V12N17.



To check for specificity of the interaction, various activated small GTPase proteins were also tested for interaction with p67 in L40 cells. RasV12, an activated form of Ras, did not interact with p67 in the assay. Similarly, RhoGV12DeltaCAAX, an activated form of RhoG lacking the C-terminal CAAX box, and an activated RhoB mutant, RhoBV14, showed no interaction with p67 able to stimulate growth in the absence of histidine (Fig. 2B). Activated forms of Rap2 (Rap2V12) and RalA (RalAV23 with 18 C-terminal amino acids deleted) were also negative in a two-hybrid assay with p67 (not shown). The various GTPases used were able to interact with their own partners (unpublished two-hybrid assays). We conclude that p67 interacts specifically with the NADPH oxidase activator Rac.

To further investigate whether p67 is a functional target for Rac, we used Rac proteins mutated in the putative effector region (amino acids 32 to 40). Substitutions of conservative residues at codon 35 (Thr Ala) or codon 38 (Asp Ala) have demonstrated in Ras studies that the effector domain is crucial for biological effects of Ras and for direct interaction with Raf(55, 56) . Identical Rac mutants have been shown unable to activate NADPH oxidase in cell-free assays (21, 22) . Here we cotransformed cells with p67 and Rac effector mutants, specifically Rac1V12 with the additional mutation Ala-35 or Ala-38. We observed that the resulting cells almost entirely lose their ability to grow in the absence of histidine (Fig. 2B), showing that interaction of Rac1 with p67 was strongly impaired by both mutations. It thus indicates that Rac effector domain plays an important role in the interaction with p67.

In all cases, hybrids of the various GTPases tested were correctly expressed and at similar levels (Fig. 2C). Histidine-independent growth has been reported here as an indication of interactions; however, equivalent induction of the other reporter gene, LacZ, was also detected by beta-galactosidase filter assay (not shown).

Altogether, these experiments clearly demonstrate that interaction between Rac and p67 is specific and Rac-GTP dependent and, in addition, involves the Rac effector domain. All these observations correlate directly with functional characteristics of Rac in the NADPH oxidase cell-free system, and thus, bring convincing evidence for p67 being the Rac-specific effector in NADPH oxidase complex. Our two-hybrid data obtained in an intracellular environment are in full agreement with in vitro results obtained with recombinant proteins and recently published by Diekmann et al.(21) and Prigmore et al.(41) . Therefore, both sets of results strongly support the view that p67 is a direct target for Rac in phagocyte NADPH oxidase.

To complement our study of Rac-p67 interaction, we wondered if activated RacL61 mutant, known to have a higher affinity for NADPH oxidase than RacV12 or Rac wild type(22) , also had a higher affinity for the p67 component. L40 cells were cotransformed with p67 encoding plasmid and plasmids encoding Rac1L61 or Rac1V12 fused to LexA. The Rac1L61 mutant appeared highly toxic in yeast cells. Therefore, although Rac1L61-induced signals appeared stronger than those from Rac1V12 (data not shown), accurate quantification of the difference could not be obtained.

Because Rac2 is the predominant Rac protein in human phagocytes (34, 40) and because the functional ``L61'' data were obtained using Rac2 (22) , we decided to use Rac2 alleles to further investigate effects of L61 mutation. Activated Rac2V12 (GTP-bound), deactivated Rac2N17 (GDP-bound), or activated Rac2L61 (GTP-bound) mutants, fused to LexA, were coexpressed in L40 cells with p67. We observed that the Rac2V12-p67 combination induced a clear histidine-independent growth (Fig. 3A). Rac2N17 allele expressed concomitantly with p67 allowed no growth in the absence of histidine as compared to control cells expressing Rac2N17 alone. On the contrary, Rac2L61 mutant induced a highly efficient growth which is clearly stronger than the growth induced by the Rac2V12 mutant. Identical observations were made using the second reporter gene, LacZ, as shown by beta-galactosidase filter assays (Fig. 3B). Quantification of interactions by measurement of beta-galactosidase activity in a liquid assay showed that Rac2L61-p67 induced a 6-fold higher signal than Rac2V12-p67 complex (Fig. 3C). Interactions between Rac2 mutants and p47 were also checked and have not been detected (data not shown). In all cases the different Rac2 alleles were checked for their expression in yeast and were found to be expressed at similar levels. These observations indicate that Rac2, like Rac1, interacts with p67 in a GTP-dependent manner, but does not seem to interact with p47. They also show that Rac2L61, in an intracellular environment, has a 6-fold higher affinity for p67 than Rac2V12. This is in agreement with a recently published report showing the higher potency of Rac1L61 recombinant protein to interact with p67(41) , and correlates directly with observations on Rac2L61 activity in the cell-free system(22) .


Figure 3: Effect of the L61 mutation on Rac-p67 interaction. In yeast strain L40, various Rac2 mutants, as fusion with LexA, were tested for interaction with p67 fused to the GAL4 activation domain. Interactions between the indicated proteins are demonstrated by histidine-independent growth or beta-galactosidase activity. A, growth in the absence of histidine are shown in the right column (-His), observations at 48 h. Control growth of cotransformed yeast in presence of histidine is shown in the left column (+His). B, beta-galactosidase activity on a filter assay, observations at 12 h. C, beta-galactosidase activity quantified by a liquid assay.



We observed that Rac2-p67 interactions were strong and comparable to positive controls but that Rac1-p67 interactions appeared relatively weak. A more precise comparison of Rac1 and Rac2 affinity for p67, using Rac V12 or L61 activated mutants fused to LexA proteins, was made directly on the same experiment. Cells coexpressing Rac1V12 or Rac2V12 and p67 grew at normal rates in the presence of histidine and were tested for their capacity to grow in the absence of histidine. In several independent experiments, Rac2V12 allowed a much better rate of growth than Rac1V12 (Fig. 4A). Similar observations were made using the other reporter gene, LacZ, as shown by a stronger beta-galactosidase activity (Fig. 4B). Quantification of Rac1- and Rac2-p67 interactions was obtained by measurement of beta-galactosidase activity in a liquid assay from the exact same number of cells. We observed that Rac2V12 induced around 6-fold more enzyme activity than Rac1V12 (Fig. 4C). It shows that LacZ reporter gene, as well as HIS3 reporter gene, are both stimulated to higher levels by the Rac2V12-p67 complex than by the Rac1V12-p67 complex. Expression of both Rac mutant proteins were checked by Western blot and were found to be similar. We tried further to compare Rac1 and Rac2 affinity for p67 using the Rac L61 mutants. Again Rac2L61-induced signals appeared clearly stronger; however, due to the high toxicity of Rac1L61 mutant we cannot provide a reliable estimation of this difference. In all, these data indicate that p67, in an intracellular environment, has a much better affinity for Rac2 protein than for Rac1 protein.

NADPH oxidase activation by small GTPase led to isolation of Rac1 from guinea pig macrophages (11) and to Rac2 from human phagocytes(12) . Whether this difference reflects a species specificity remains to be determined. However, the predominant interaction of p67 with Rac2 that we observed provide new information relevant to this question. Our data, in combination with the fact that human phagocytes contain predominantly Rac2 rather than Rac1(34, 40) , show that the Rac-p67 interaction in a whole cell environment is almost specific for Rac2 protein.

This raises the question of the molecular basis for the difference between Rac2 and Rac1. We showed that the Rac-p67 interaction involved the Rac GTP-binding site and required the Rac effector domain. Rac2 and Rac1 are almost identical in these areas; however, the C-terminal portions of the two proteins are divergent. This suggests that the basis for the p67 higher interaction efficiency with Rac2 probably resides in that C-terminal part of Rac2.

In the recombinant cell-free system, Rac1 and Rac2 are roughly equipotent in NADPH oxidase activation. However, it has been previously observed that Rac2 was a more potent activator than Rac1 when neutrophil cytosol was present in the assay(24) , thus indicating involvement of additional intracellular factor(s). The yeast cells could also provide such an environment and allow Rac2 to interact more efficiently with p67 than Rac1.

Our data are in favor of p67 being the Rac target in NADPH oxidase. However, we cannot exclude that, in addition, Rac could directly act on cytochrome b(23, 40, 57) or, as suggested very recently(58) , that Rac could act through activation of p21-activated kinases (PAK1 and PAK2). Our data in combination with current knowledge on Rac1 function could also suggest that in human neutrophils, Rac2 could have a different function than Rac1: Rac2 regulating NADPH oxidase activity and Rac1 perhaps regulating cytoskeleton modifications.

Overall, we conclude that Rac2 can regulate the human NADPH oxidase by interacting in a GTP-dependent manner directly with the p67 component. The Rac2-p67 interaction, probably occurring at the plasma membrane level(1, 33) , would not promote assembly at the membrane of cytosolic components(35) , but would rather directly activate the assembled membranous complex, thus stimulating superoxide production.


FOOTNOTES

*
This work was supported in part by the ``Institut National de la Santé et de la Recherche Médicale'' (INSERM) and by grants from the ``Association pour la Recherche sur le Cancer'' and from the Comité de Paris de la ``Ligue Nationale contre le Cancer.'' The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Recipient of a fellowship from Association pour la Recherche sur le Cancer (ARC).

To whom correspondence should be addressed: Institut Cochin de Génétique Moléculaire, INSERM U. 257, 24 rue du Fbg St. Jacques, 75014 Paris, France. Fax: 33-1-4441-2462; Tel: 33-1-4441-2463.

(^1)
The abbreviations used are: GAL4 AD, GAL4 activation domain; ECL, enhanced chemiluminescence.

(^2)
V. Jung and J. Camonis, unpublished data.


ACKNOWLEDGEMENTS

We thank J. Jami and A. Tavitian for interest and support. We are grateful to A. Hall for the rac1 plasmids. Hybrid constructs encoding small G proteins were generously provided by A. Vojtek (Ras), S. Doulet-Brutin (RhoG), G. Zalcman and B. Oloffson (RhoB), I. Janoueix-Lerosey (Rap2), and V. Jullien (RalA). We thank L. Morin for technical assistance.


REFERENCES

  1. Bokoch, G. M. (1995) Trends Cell Biol. 5, 109-113 [CrossRef]
  2. Chanock, S. J., El Benna, J., Smith, R. M., and Babior, B. M. (1994) J. Biol. Chem. 269, 24519-24522 [Free Full Text]
  3. Morel, F., Doussiere, J., and Vignais, P. V. (1991) Eur. J. Biochem. 201, 523-546 [Abstract]
  4. Curnutte, J. T. (1993) Clin. Immunol. Immunopathol. 67, S2-S15
  5. Orkin, S. H. (1989) Annu. Rev. Immunol. 7, 277-307 [CrossRef][Medline] [Order article via Infotrieve]
  6. Clark, R. A., Malech, H. L., Gallin, J. I., Nunoi, H., Volpp, B. D., Pearson, D. W., Nauseef, W. M., and Curnutte, J. T. (1989) N. Engl. J. Med. 321, 647-652 [Abstract]
  7. Rotrosen, D., Yeung, C. L., Leto, T. L., Malech, H. L., and Kwong, C. H. (1992) Science 256, 1459-1462 [Medline] [Order article via Infotrieve]
  8. Abo, A., Boyhan, A., West, I., Thrasher, A. J., and Segal, A. W. (1992) J. Biol. Chem. 267, 16767-16770 [Abstract/Free Full Text]
  9. Lomax, K. J., Leto, T. L., Nunoi, H., Gallin, J. I., and Malech, H. L. (1989) Science 245, 409-412 [Medline] [Order article via Infotrieve]
  10. Leto, T. L., Lomax, K. J., Volpp, B. D., Nunoi, H., Sechler, J. M., Nauseef, W. M., Clark, R. A., Gallin, J. I., and Malech, H. L. (1990) Science 248, 727-730 [Medline] [Order article via Infotrieve]
  11. Abo, A., Pick, E., Hall, A., Totty, N., Teahan, C. G., and Segal, A. W. (1991) Nature 353, 668-670 [CrossRef][Medline] [Order article via Infotrieve]
  12. Knaus, U. G., Heyworth, P. G., Evans, T., Curnutte, J. T., and Bokoch, G. M. (1991) Science 254, 1512-1515 [Medline] [Order article via Infotrieve]
  13. Dorseuil, O., Vazquez, A., Lang, P., Bertoglio, J., Gacon, G., and Leca, G. (1992) J. Biol. Chem. 267, 20540-20542 [Abstract/Free Full Text]
  14. Gabig, T. G., Crean, C. D., Mantel, P. L., and Rosli, R. (1995) Blood 85, 804-811 [Abstract/Free Full Text]
  15. Quinn, M. T., Parkos, C. A., Walker, L., Orkin, S. H., Dinauer, M. C., and Jesaitis, A. J. (1989) Nature 342, 198-200 [CrossRef][Medline] [Order article via Infotrieve]
  16. Maly, F. E., Quilliam, L. A., Dorseuil, O., Der, C. J., and Bokoch, G. M. (1994) J. Biol. Chem. 269, 18743-18746 [Abstract/Free Full Text]
  17. Wientjes, F. B., Hsuan, J. J., Totty, N. F., and Segal, A. W. (1993) Biochem. J. 296, 557-561 [Medline] [Order article via Infotrieve]
  18. Someya, A., Nagaoka, I., and Yamashita, T. (1993) FEBS Lett. 330, 215-218 [CrossRef][Medline] [Order article via Infotrieve]
  19. Fuchs, A., Dagher, M. C., and Vignais, P. V. (1995) J. Biol. Chem. 270, 5695-5697 [Abstract/Free Full Text]
  20. Voncken, J. W., van Schaick, H., Kaartinen, V., Deemer, K., Coates, T., Landing, B., Pattengale, P., Dorseuil, O., Bokoch, G. M., Groffen, J., and Heisterkamp, N. (1995) Cell 80, 719-728 [Medline] [Order article via Infotrieve]
  21. Diekmann, D., Abo, A., Johnston, C., Segal, A. W., and Hall, A. (1994) Science 265, 531-533 [Medline] [Order article via Infotrieve]
  22. Xu, X., Barry, D. C., Settleman, J., Schwartz, M. A., and Bokoch, G. M. (1994) J. Biol. Chem. 269, 23569-23574 [Abstract/Free Full Text]
  23. Freeman, J. L., Kreck, M. L., Uhlinger, D. J., and Lambeth, J. D. (1994) Biochemistry 33, 13431-13435 [Medline] [Order article via Infotrieve]
  24. Heyworth, P. G., Knaus, U. G., Xu, X., Uhlinger, D. J., Conroy, L., Bokoch, G. M., and Curnutte, J. T. (1993) Mol. Biol. Cell 4, 261-269 [Abstract]
  25. Ando, S., Kaibuchi, K., Sasaki, T., Hiraoka, K., Nishiyama, T., Mizuno, T., Asada, M., Nunoi, H., Matsuda, I., Matsuura, Y., Polakis, P., McCormick, F., and Takai, Y. (1992) J. Biol. Chem. 267, 25709-25713 [Abstract/Free Full Text]
  26. Clark, R. A., Volpp, B. D., Leidal, K. G., and Nauseef, W. M. (1990) J. Clin. Invest. 85, 714-721 [Medline] [Order article via Infotrieve]
  27. Quinn, M. T., Evans, T., Loetterle, L. R., Jesaitis, A. J., and Bokoch, G. M. (1993) J. Biol. Chem. 268, 20983-20987 [Abstract/Free Full Text]
  28. El Benna, J., Ruedi, J. M., and Babior, B. M. (1994) J. Biol. Chem. 269, 6729-6734 [Abstract/Free Full Text]
  29. Park, J. W., Ma, M., Ruedi, J. M., Smith, R. M., and Babior, B. M. (1992) J. Biol. Chem. 267, 17327-17332 [Abstract/Free Full Text]
  30. Leto, T. L., Adams, A. G., and de Mendez, I. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10650-10654 [Abstract/Free Full Text]
  31. Leusen, J. H., Bolscher, B. G., Hilarius, P. M., Weening, R. S., Kaulfersch, W., Seger, R. A., Roos, D., and Verhoeven, A. J. (1994) J. Exp. Med. 180, 2329-2334 [Abstract]
  32. Le Cabec, V., Mohn, H., Gacon, G., and Maridonneau-Parini, I. (1994) Biochem. Biophys. Res. Commun. 198, 1216-1224 [CrossRef][Medline] [Order article via Infotrieve]
  33. Fuchs, A., Dagher, M. C., Jouan, A., and Vignais, P. V. (1994) Eur. J. Biochem. 226, 587-595 [Abstract]
  34. Abo, A., Webb, M. R., Grogan, A., and Segal, A. W. (1994) Biochem. J. 3, 585-591
  35. Dorseuil, O., Quinn, M. T., and Bokoch, G. M. (1995) J. Leukocyte Biol. 58, 108-113 [Abstract]
  36. Finan, P., Shimizu, Y., Gout, I., Hsuan, J., Truong, O., Butcher, C., Bennett, P., Waterfield, M. D., and Kellie, S. (1994) J. Biol. Chem. 269, 13752-13755 [Abstract/Free Full Text]
  37. Sumimoto, H., Kage, Y., Nunoi, H., Sasaki, H., Nose, T., Fukumaki, Y., Ohno, M., Minakami, S., and Takeshige, K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5345-5349 [Abstract]
  38. de Mendez, I., Garrett, M. C., Adams, A. G., and Leto, T. L. (1994) J. Biol. Chem. 269, 16326-16332 [Abstract/Free Full Text]
  39. Uhlinger, D. J., Taylor, K. L., and Lambeth, J. D. (1994) J. Biol. Chem. 269, 22095-22098 [Abstract/Free Full Text]
  40. Heyworth, P. G., Bohl, B. P., Bokoch, G. M., and Curnutte, J. T. (1994) J. Biol. Chem. 269, 30749-30752 [Abstract/Free Full Text]
  41. Prigmore, E., Ahmed, S., Best, A., Kozma, R., Manser, E., Segal, A. W., and Lim, L. (1995) J. Biol. Chem. 270, 10717-10722 [Abstract/Free Full Text]
  42. Fields, S., and Song, O. (1989) Nature 340, 245-246 [CrossRef][Medline] [Order article via Infotrieve]
  43. Chien, C. T., Bartel, P. L., Sternglanz, R., and Fields, S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9578-9582 [Abstract]
  44. Chardin, P., Camonis, J. H., Gale, N. W., van, A. L., Schlessinger, J., Wigler, M. H., and Bar, S. D. (1993) Science 260, 1338-1343 [Medline] [Order article via Infotrieve]
  45. Bartel, P. L., and Fields, S. (1996) Methods Enzymol., in press
  46. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214 [Medline] [Order article via Infotrieve]
  47. Hannon, G. J., Demetrick, D., and Beach, D. (1993) Genes & Dev. 7, 2378-2391
  48. Sherman, F., Fink, G. R., and Hicks, J. B. (1986) Methods in Yeast Genetics , Revised Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  49. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401-410 [Medline] [Order article via Infotrieve]
  50. Moreau, P. (1987) J. Mol. Biol. 194, 621-634 [Medline] [Order article via Infotrieve]
  51. Kuras, L., and Thomas, D. (1995) Mol. Cell. Biol. 15, 208-216 [Abstract]
  52. Heyworth, P. G., Curnutte, J. T., Nauseef, W. M., Volpp, B. D., Pearson, D. W., Rosen, H., and Clark, R. A. (1991) J. Clin. Invest. 87, 352-356 [Medline] [Order article via Infotrieve]
  53. Didsbury, J. R., Uhing, R. J., and Snyderman, R. (1990) Biochem. Biophys. Res. Commun. 171, 804-812 [Medline] [Order article via Infotrieve]
  54. Van Aelst, L., Barr, M., Marcus, S., Polverino, A., and Wigler, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6213-6217 [Abstract]
  55. Zhang, X.-F., Settleman, J., Kyriakis, J. M., Takeuchi-Suzuki, E., Elledge, S. J., Marshall, M. S., Bruder, J. T., Rapp, U. R., and Avruch, J. (1993) Nature 364, 308-313 [CrossRef][Medline] [Order article via Infotrieve]
  56. Warne, P. H., Viciana, P. R., and Downward, J. (1993) Nature 364, 352-355 [CrossRef][Medline] [Order article via Infotrieve]
  57. Kreck, M. L., Uhlinger, D. J., Tyagi, S. R., Inge, K. L., and Lambeth, J. D. (1994) J. Biol. Chem. 269, 4161-4168 [Abstract/Free Full Text]
  58. Knaus, U. G., Morris, S., Dong, H. J., Chernoff, J., and Bokoch, G. M. (1995) Science 269, 221-223 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.